Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast Cancer

NCT04174742 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT04174742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04174742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast Cancer
Lead sponsor
Wake Forest University Health Sciences
Phase
Observational
Overall status
Active, not recruiting
Start date
December 17, 2019
Completion date
January 31, 2041
Enrollment
115 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast, breast cancer